ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy-Reference-Cited by-同舟云学术

ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy

Published:2020-08 Issue:2 Volume:86 Page:315-324
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Nomura Hisanaga^ORCID,Tsuji Daiki,Demachi Ken,Mochizuki Nobuo,Matsuzawa Haruki,Yano Tomonori,Daiko Hiroyuki,Fujii Satoshi,Kojima Takashi,Itoh Kunihiko,Kawasaki Toshikatsu

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-020-04118-9.pdf

Reference44 articles.

1. Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M, Hosoya Y (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104(11):1455–1460. https://doi.org/10.1111/cas.12274

2. Aslani A, Smith RC, Allen BJ, Pavlakis N, Levi JA (2000) The predictive value of body protein for chemotherapy-induced toxicity. Cancer 88(4):796–803. https://doi.org/10.1002/(sici)1097-0142(20000215)88:4%3c796:aid-cncr10%3e3.0.co;2-p

3. Voog E, Bienvenu J, Warzocha K, Moullet I, Dumontet C, Thieblemont C, Monneret G, Gutowski MC, Coiffier B, Salles G (2000) Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. J Clin Oncol 18(2):325–331. https://doi.org/10.1200/JCO.2000.18.2.325

4. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D (2000) A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 37(3–4):351–360. https://doi.org/10.3109/10428190009089435

5. Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, Dale DC (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117(9):1917–1927. https://doi.org/10.1002/cncr.25691

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic polymorphisms and platinum-induced hematological toxicity: a systematic review;Frontiers in Pharmacology;2024-08-21

2. Elemental diet preventative effects for adverse events during chemotherapy in patients with esophageal cancer - A systematic review and meta-analysis;Nutrición Hospitalaria;2024

3. Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer;Cancer Chemotherapy and Pharmacology;2023-10-28

4. Effects of gene polymorphisms on delayed MTX clearance, toxicity, and metabolomic changes after HD-MTX treatment in children with acute lymphoblastic leukemia;European Journal of Pediatrics;2023-10-18

5. Effects of gene polymorphisms on delayed MTX clearance, toxicity, and metabolomic changes after HD-MTX treatment in children with acute lymphoblastic leukemia;2023-07-14